News for Spero Therapeutics, Inc. (SPRO)

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. ( SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused

**media[550000]**

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. ( SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused

Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential. Read more to see why I rate SPRO stock a buy.

Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

**media[511560]**

Esther Rajavelu named Interim President & CEO of Spero Therapeutics amid leadership changes due to SEC disclosures.

Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -18.52% and 41.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[459669]**

Shares of Alphabet Inc. GOOGL GOOG rose sharply in today's pre-market trading after the company reported better-than-expected third-quarter financial results. ...

Spero Therapeutics (SPRO) stock tumbled 20% post-market after the company announced it was cutting its workforce by 39% in the wake of a failed Phase 2 study for its drug SPR720.

Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active...

In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article 5 Cheap Penny Stocks to Buy According...

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

California-based biopharmaceutical company Spruce Biosciences, Inc. (SPRB) is down over 77% in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February trading metrics.

In this article, we will take a detailed look at the 11 Hyper-Growth Stocks Billionaires Are Loading Up On. For a quick overview of such stocks, read our article 5 Hyper-Growth Stocks Billionaires Are Loading Up On. Growth stocks have rewarded investors over the past several years, thanks to the hyper growth and mind-numbing expansion of technology companies […]

The global urinary tract infections therapeutics market size was valued at USD 8.92 billion in 2022. It is estimated to reach an expected value of USD...